Myoform Moves From Waitlist to Public Launch With AI-Driven Personalised Supplement Platform

Myoform today announced the public launch of its personalised nutrition platform, opening access following a successful soft launch to a waitlist of more than 1,000 users in late 2025. Designed for athletes and highly active individuals, Myoform applies the principles of precision medicine to sports performance and proactive health, using advanced data inputs and AI to deliver truly individualised supplementation.

The launch addresses a longstanding problem in sports nutrition: most supplements are built for the average consumer, despite wide variation in genetics, biomarkers, training load, lifestyle, and recovery capacity. Myoform’s platform is designed to replace generic recommendations with N-of-1 formulations—bespoke, powder-based supplements tailored to the individual and taken as a single daily scoop.

How Myoform works

Myoform combines whole-genome sequencing, blood biomarkers, wearable and biometric data, and lifestyle inputs into a unified performance profile. This data is analysed using the company’s AI-driven platform to generate hyper-contextual insights and translate them into a personalised supplement formulation. Users can complete Myoform’s testing process or upload existing genetic and blood test data, reducing friction and cost for those already engaged in performance tracking.

The result is a personalised nutrition plan that evolves as inputs change, aligning supplementation with training demands, recovery needs, and lifestyle context. The platform integrates both insight—clear, evidence-informed reporting—and intervention through bespoke supplements, rather than separating analysis from action.

Why the market needs change

The global supplements market has expanded rapidly, but personalisation has largely meant surface-level surveys or broad “goal-based” stacks. These approaches fail to account for biological variability and often rely on static formulations that do not adapt over time. For athletes and highly active individuals, this gap can mean unnecessary supplementation, missed opportunities for optimisation, or inconsistent outcomes.

At the same time, advances in genomics, biomarker testing, and wearable technology have made individual-level data more accessible than ever. Myoform’s launch reflects a shift toward applying these tools in a cohesive, consumer-ready system that prioritises relevance, restraint, and measurable support for performance.

A differentiated approach to personalised supplements

Myoform is intentionally positioned away from one-size-fits-all products and influencer-led wellness brands. Its platform is built around precision medicine principles—using multiple data sources to inform decisions at the individual level—while remaining firmly focused on performance rather than disease treatment.

Key differentiators include:

• Use of whole-genome sequencing alongside dynamic biomarkers and wearable data

• AI-driven analysis designed to support N-of-1 personalisation rather than population averages

• Powder-based formulations tailored to each user, updated over time

• A single daily scoop, simplifying adherence without diluting personalisation

• Clear separation between insights and interventions, delivered through one platform

Founder perspective

“Our goal was not to create another supplement brand, but to rethink how performance nutrition should work when you start from the individual,” said the Founder and CEO of Myoform. “Athletes and highly active people already generate enormous amounts of data about their bodies and training. Myoform exists to make that data actionable in a way that is practical, evidence-informed, and sustainable—without overpromising or oversimplifying the science.”

Scientific credibility and early validation

Myoform’s platform and formulation methodology are developed by a multidisciplinary team spanning performance science, nutrition, and data science. The company’s technology is patent-pending, and insights are grounded in established research linking genetics, biomarkers, and nutrient metabolism. During the late-2025 soft launch, early users from the waitlist provided feedback that informed refinements to reporting clarity, formulation delivery, and user experience.

Launch details and access

The public launch on 19 January 2026 opens Myoform to new users in the UK and US. Initial testing is priced at USD $399 (approximately £299), with the option to upload existing genetic or blood test data. Personalised supplement subscriptions begin at USD $99 per month, covering ongoing formulation updates and delivery.

The launch marks Myoform’s transition from private beta to general availability, with continued emphasis on measured growth, scientific discipline, and long-term trust with athletes, practitioners, and partners.